Obel Lasse M, Skovbo Joachim S, Diederichsen Axel C P, Thomassen Mads, Kjær Lasse, Larsen Morten K, Knudsen Trine A, Skov Vibe, Kruse Torben A, Burton Mark, Dembic Maja, Wienecke Troels, Sabater-Lleal Maria, Gerke Oke, Bruun Niels E, Ellervik Christina, Brabrand Mette, Steffensen Flemming H, Frost Lars, Lambrechtsen Jess, Busk Martin, Urbonaviciene Grazina, Egstrup Kenneth, Karon Marek, Feddersen Søren, Rasmussen Lars M, Hasselbalch Hans C, Lindholt Jes S
Elite Centre for Individualized Medicine in Arterial Disease (L.M.O., J.S.S., A.C.P.D., L.M.R., J.S.L.), Odense University Hospital, Denmark.
Departments of Cardiothoracic and Vascular Surgery (L.M.O., J.S.S., J.S.L.), Odense University Hospital, Denmark.
Circulation. 2025 Aug 5;152(5):300-312. doi: 10.1161/CIRCULATIONAHA.125.074002. Epub 2025 Jun 4.
The somatic sequence variation, a key driver of myeloproliferative neoplasms, has been associated with increased risk of aortic aneurysms. This study aimed to explore associations between the variant allele frequency (VAF) and ascending, descending, and abdominal aortic aneurysms.
In the DANCAVAS I and II trials (Danish Cardiovascular Screening), 15 000 individuals underwent cardiovascular risk assessments including blood samples and noncontrast ECG-gated computed tomography scans. In this cross-sectional substudy, individuals with screening-detected aortic aneurysms (≥45 mm ascending, ≥35 mm descending, or ≥30 mm abdominal), random aneurysm-free male controls, and all women (only included during the DANCAVAS I pilot study) were tested for the sequence variation.
A total of 8056 individuals (90.9% men, mean age 68±4 years) were tested for the sequence variation, which presented an overall prevalence of 7.1%. Ascending, descending, and abdominal aneurysm prevalences were 6.6%, 2.9%, and 6.8%, respectively. In -negative participants (n=7486), -positive participants with VAF <1% (n=491), and -positive participants with VAF ≥1% (n=79), ascending aortic aneurysms were observed in 6.4%, 9.0%, and 16.5%, respectively (<0.001). No significant differences were observed across sequence variation groups for descending and abdominal aneurysms. Among -positive individuals, the median VAF was higher in those with ascending aneurysm (9.5%; interquartile range, 3.0-40.0) than in controls (4.4%; interquartile range, 1.8-20.0; =0.021). Ascending aortic diameter correlated modestly with VAF (Spearman ρ=0.10; =0.026). No significant correlations were observed for descending or abdominal diameters. For ascending aneurysms, VAF <1% and ≥1% presented adjusted odds ratios of 1.4 (95% CI, 1.01-2.0; =0.045) and 2.7 (95% CI, 1.5-5.1; =0.002), respectively, compared with -negative controls. For each doubling in VAF, the risk for ascending aneurysm increased by 11% (=0.013). The sequence variation was not significantly associated with descending or abdominal aneurysms after adjusting for covariates and using these VAF thresholds.
In a study population of primarily men 60 to 74 years of age, the somatic sequence variation was strongly and independently associated with ascending aortic aneurysms, presenting a positive correlation between aneurysm size and VAF. No convincing associations were observed for descending or abdominal aneurysms. Screening patients with larger ascending aortic aneurysms for the sequence variation, and vice versa, screening -positve individuals presenting higher VAFs for ascending aneurysms, may be clinically appropriate.
体细胞序列变异是骨髓增殖性肿瘤的关键驱动因素,与主动脉瘤风险增加相关。本研究旨在探讨变异等位基因频率(VAF)与升主动脉、降主动脉和腹主动脉瘤之间的关联。
在DANCAVAS I和II试验(丹麦心血管筛查)中,15000名个体接受了心血管风险评估,包括血液样本采集和非增强心电图门控计算机断层扫描。在这项横断面亚研究中,对筛查发现主动脉瘤(升主动脉≥45mm、降主动脉≥35mm或腹主动脉≥30mm)的个体、随机选取的无动脉瘤男性对照以及所有女性(仅在DANCAVAS I试点研究期间纳入)进行序列变异检测。
共有8056名个体(90.9%为男性,平均年龄68±4岁)接受了序列变异检测,总体患病率为7.1%。升主动脉、降主动脉和腹主动脉瘤的患病率分别为6.6%、2.9%和6.8%。在序列变异阴性参与者(n = 7486)、VAF<1%的序列变异阳性参与者(n = 491)和VAF≥1%的序列变异阳性参与者(n = 79)中,升主动脉瘤的观察患病率分别为6.4%、9.0%和16.5%(P<0.001)。在序列变异组中,降主动脉瘤和腹主动脉瘤未观察到显著差异。在序列变异阳性个体中,升主动脉瘤患者的VAF中位数(9.5%;四分位间距,3.0 - 40.0)高于对照组(4.4%;四分位间距,1.8 - 20.0;P = 0.021)。升主动脉直径与VAF呈适度相关(Spearman ρ = 0.10;P = 0.026)。降主动脉或腹主动脉直径未观察到显著相关性。对于升主动脉瘤,与序列变异阴性对照相比,VAF<1%和≥1%的调整后比值比分别为1.4(95%CI,1.01 - 2.0;P = 0.045)和2.7(95%CI,1.5 - 5.1;P = 0.002)。VAF每增加一倍,升主动脉瘤风险增加11%(P = 0.013)。在调整协变量并使用这些VAF阈值后,序列变异与降主动脉瘤或腹主动脉瘤无显著关联。
在主要为60至74岁男性的研究人群中,体细胞序列变异与升主动脉瘤密切且独立相关,动脉瘤大小与序列变异VAF呈正相关。降主动脉瘤或腹主动脉瘤未观察到令人信服的关联。对升主动脉瘤较大的患者进行序列变异筛查,反之,对序列变异阳性且VAF较高的个体进行升主动脉瘤筛查,可能在临床上是合适的。